Mometasone Nasal Spray   3

Background
The Department of Veterans Affairs (VA) and the Department of Defense (DOD) acquire their pharmaceutical requirements through their respective Pharmaceutical Prime Vendor (PPV) Programs. The purpose of this solicitation is to establish a supply source that will provide the drugs listed in the schedule for purchase through the PPV Programs. The total annual estimated usage for VA, Federal Health Care Center (FHCC), State Veterans Homes - Option 2 (SVH), DOD, Indian Health Service (IHS), and Bureau of Prisons (BOP) appears on the Schedule of Supplies section of this Solicitation.

Work Details
The specific product to be manufactured or delivered under the contract is Mometasone Furoate Monohydrate 50MCG/Actuation; Suspension, Nasal, 17GM. One award will be made for line item one (1). To be considered for award, offerors must submit a price for the base year and all four one-year options for line item one (1). Prices offered shall not exceed two decimal places. Offered prices must include the Cost Recovery Fee of 0.5% as outlined in Scope of Contract. Offerors must list an 11 digit NDC number for each offered drug that is unique to the Offeror's company as outlined in scope of contract.

Period of Performance
The contract will be effective on the date the government signs the SF1449 and notifies the offeror (contractor) of award. The Implementation Period begins at the expiration of the Implementation Period. The base year Ordering Period will be in effect for the period of one (1) year.

Place of Performance
All Department of Veterans Affairs (VA) facilities, All Ordering Activities under the Department of Defense (DOD) Pharmaceutical Prime Vendor Program, All Indian Health Service (IHS) facilities, All Bureau of Prisons (BOP) facilities, Captain James A. Lovell Federal Health Care Center (FHCC), All Option 2 State Veteran Homes